ScreenerHero

BDRXBiodexa Pharmaceuticals plc American Depositary Shs

NAS · US · Healthcare · Biotechnology · biodexapharma.com
1.270USDMkt Cap: 1.15M $P/E: —

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 di…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.15M $
Enterprise Value-7.65M $
Revenue (TTM)—
Gross Profit-3.96M $
Net Income (TTM)-6.38M $
Revenue/Share—
Last Price1.270 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees11
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)Infinity
PEG—
EV/EBITDA0.89
EV/Revenue—
P/S—
P/B0.04
EPS (TTM)-67.99
EPS (Forward)0.00
52W Range
1.21552% of range1.320
52W High1.320 USD
52W Low1.215 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.98%
ROA-35.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.59M $
CapEx (TTM)691.00K $
FCF Margin—
FCF Yield-87.38%
Net Debt-8.47M $
Net Debt/EBITDA0.99
Balance Sheet
Debt/Equity0.01
Current Ratio2.03
Quick Ratio1.43
Book Value/Sh34.18 USD
Cash/Share13.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 3, 2020
Splits
Last Split1:5
Split DateApr 6, 2026
Analyst Consensus
Rating—
Target (Mean)10.30 USD
Upside (mean)+711.4%
Target Range10.30 USD – 10.30 USD
# Analysts1
Ownership
Shares Out.904.07K
Float594.40K
Insiders0.00%
Institutions1.94%
Short Interest
Short Ratio0.1d
Short % Float2.41%
Short % Out.2.41%
Shares Short24.82K
Short (prev mo.)67.33K
Technical
SMA 502.120 (-40.1%)
SMA 2008.195 (-84.5%)
Beta1.21
S&P 52W Chg19.18%
Avg Vol (30d)55.79K
Avg Vol (10d)151.12K
Technical Indicators
RSI (14)29.0
MACD-0.2199
MACD Signal-0.2398
MACD Hist.+0.0199
BB Upper1.676 USD
BB Middle1.456 USD
BB Lower1.236 USD
BB Width30.23%
ATR (14)0.1993 USD
Vol Ratio (20d)0.38x